RYAM Raises €67 million Green Capital to Invest in its Biomaterials Strategy
Rayonier Advanced Materials (RYAM) has secured €67 million in green capital financing, comprising €37 million in secured term loans from French banks at ~5% interest rate with 7-year maturity, and €30 million in preferred equity from Swen Capital Partners. The latter investment represents a 20% stake in RYAM BioNova S.A.S., valuing the new entity at over $160 million. The funds will support BioNova's growth initiatives, including a second-generation bioethanol plant and prebiotics project, with projected EBITDA of over $40 million by 2027.
Rayonier Advanced Materials (RYAM) ha ottenuto 67 milioni di euro in finanziamenti green, di cui 37 milioni in prestiti a lungo termine garantiti da banche francesi a un tasso di interesse di circa il 5% con scadenza a 7 anni, e 30 milioni in capitale di rischio preferenziale da Swen Capital Partners. Quest'ultimo investimento rappresenta una quota del 20% in RYAM BioNova S.A.S., valutando la nuova entità a oltre 160 milioni di dollari. I fondi supporteranno le iniziative di crescita di BioNova, incluso un impianto di bioetanolo di seconda generazione e un progetto sui prebiotici, con un EBITDA previsto di oltre 40 milioni di dollari entro il 2027.
Rayonier Advanced Materials (RYAM) ha asegurado 67 millones de euros en financiamiento verde, que comprende 37 millones en préstamos a plazo garantizados por bancos franceses a una tasa de interés de aproximadamente el 5% con un vencimiento de 7 años, y 30 millones en capital preferente de Swen Capital Partners. Esta última inversión representa una participación del 20% en RYAM BioNova S.A.S., valorando la nueva entidad en más de 160 millones de dólares. Los fondos apoyarán las iniciativas de crecimiento de BioNova, incluyendo una planta de bioetanol de segunda generación y un proyecto de prebióticos, con un EBITDA proyectado de más de 40 millones de dólares para 2027.
레이온이어 어드밴스드 머티리얼즈 (RYAM)는 6,700만 유로의 그린 자본 금융을 확보했습니다. 이 자금은 5%의 이자율로 7년 만기인 프랑스 은행에서 보장된 장기 대출 3,700만 유로와 스웬 캐피탈 파트너스의 우선주 3,000만 유로로 구성됩니다. 후자의 투자는 RYAM BioNova S.A.S.의 20% 지분을 나타내며, 새로운 실체의 가치는 1억 6천만 달러를 초과합니다. 이 자금은 BioNova의 성장 이니셔티브를 지원하며, 여기에는 2세대 바이오에탄올 공장과 프리바이오틱스 프로젝트가 포함되어 있으며, 2027년까지 4천만 달러 이상의 EBITDA가 예상됩니다.
Rayonier Advanced Materials (RYAM) a sécurisé 67 millions d'euros de financement en capital vert, comprenant 37 millions d'euros de prêts à terme garantis par des banques françaises à un taux d'intérêt d'environ 5% avec une maturité de 7 ans, et 30 millions d'euros en actions privilégiées provenant de Swen Capital Partners. Cet investissement représente une participation de 20% dans RYAM BioNova S.A.S., valorisant la nouvelle entité à plus de 160 millions de dollars. Les fonds soutiendront les initiatives de croissance de BioNova, y compris une usine de bioéthanol de deuxième génération et un projet de prébiotiques, avec une EBITDA prévue de plus de 40 millions de dollars d'ici 2027.
Rayonier Advanced Materials (RYAM) hat 67 Millionen Euro an grüner Kapitalfinanzierung gesichert, die aus 37 Millionen Euro an gesicherten Terminkrediten von französischen Banken mit einem Zinssatz von etwa 5% und einer Laufzeit von 7 Jahren sowie 30 Millionen Euro an bevorzugtem Eigenkapital von Swen Capital Partners besteht. Letztere Investition repräsentiert einen 20%-Anteil an RYAM BioNova S.A.S., der das neue Unternehmen mit über 160 Millionen Dollar bewertet. Die Mittel werden die Wachstumsinitiativen von BioNova unterstützen, darunter eine Biokraftstoffanlage der zweiten Generation und ein Präbiotika-Projekt, mit einem EBITDA von über 40 Millionen Dollar bis 2027.
- Secured €67 million in green capital financing
- Favorable 5% initial floating rate on €37 million term loans
- BioNova subsidiary valued at over $160 million
- Projected EBITDA of over $40 million from new initiatives by 2027
- 20% stake dilution in BioNova subsidiary to Swen Capital Partners
Insights
This significant green financing deal strengthens RYAM's balance sheet and strategic position in biomaterials. The
The projected
The creation of RYAM BioNova represents a strategic pivot towards high-growth sustainable materials markets. The second-generation bioethanol plant is particularly noteworthy as it targets advanced biofuels from non-food biomass, addressing both environmental concerns and regulatory requirements. The prebiotics project signals entry into the growing functional ingredients market, diversifying revenue streams beyond traditional cellulose products.
The green financing structure validates RYAM's sustainability strategy and could serve as a template for future capital raises. This positions RYAM at the forefront of the bio-based materials transition, potentially capturing premium valuations associated with green technology companies.
SWEN’s investment in BioNova reflects a valuation of greater than
"The formation of BioNova and this latest round of financing are pivotal in our strategic push into biomaterials," said De Lyle Bloomquist, President and CEO of RYAM. "With this green capital, we are poised to drive over
About RYAM
RYAM is a global leader in the production of cellulose-based products, specializing in high purity cellulose specialties, a plant-based polymer commonly used in the production of filters, food, pharmaceuticals, and other industrial applications. RYAM’s specialized assets are also used to produce biofuels, bioelectricity, and other biomaterials such as bioethanol and tall oils. The company also manufactures products for the paper and packaging markets. With manufacturing operations in the
About SWEN Capital Partners
SWEN Capital Partners (“SWEN CP”) is a benchmark player in sustainable investments with more than
SWEN CP supports entrepreneurs and its partners on social, societal and/or environmental issues and the creation of sustainable value, essential in its eyes for useful finance. To learn more please visit https://www.swen-cp.fr/en.
Forward-Looking Statements
Certain statements in this document regarding anticipated financial, business, legal, or other outcomes, including business and market conditions, outlook, and other similar statements relating to Rayonier Advanced Materials’ or future or expected events, developments, or financial or operational performance or results, are "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These forward-looking statements are identified by the use of words such as "may," "will," "should," "expect," "estimate," "believe," "intend," "anticipate," and other similar language. However, the absence of these or similar words or expressions does not mean that a statement is not forward-looking. While we believe these forward-looking statements are reasonable when made, forward-looking statements are not guarantees of future performance or events, and undue reliance should not be placed on these statements. Although we believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, we can give no assurance that these expectations will be attained. It is possible that actual results may differ materially from those indicated by these forward-looking statements due to a variety of risks and uncertainties.
Other important factors that could cause actual results or events to differ materially from those expressed in forward-looking statements that may have been made in this document are described or will be described in our filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112035273/en/
Media
Ryan Houck
904-357-9134
Investors
Mickey Walsh
904-357-9162
Source: Rayonier Advanced Materials Inc.
FAQ
How much green capital did RYAM raise in its latest financing round?
What is the interest rate and maturity of RYAM's new term loans?
What is the valuation of RYAM's BioNova subsidiary?
What is RYAM's projected EBITDA from the new BioNova initiatives by 2027?
